RecruitingPhase 3NCT06165341
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Studying Alpha-1-antitrypsin deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Fazirsiran Injection(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Mayo Clinic - PPDS, Phoenix, Arizona, United States
- University of Arizona Thomas D. Boyer Liver Institute, Tucson, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- UCLA Pulmonary and Critical Care, Los Angeles, California, United States
- University of California Benioff Children's Hospital, San Francisco, California, United States
- Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
- Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
- Indiana University School of Medicine-Indianapolis, Indianapolis, Indiana, United States
- University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
- Boston Medical Center, Boston, Massachusetts, United States
- University of Michigan Hospital - 1500 E Medical Center Dr, Ann Arbor, Michigan, United States
- Henry Ford Health System, Novi, Michigan, United States
- Mayo Clinic PPDS, Rochester, Minnesota, United States
- NYU Langone Medical Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06165341 on ClinicalTrials.govOther trials for Alpha-1-antitrypsin deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07431112A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)AIRNA Corporation
- RECRUITINGPHASE4NCT07135427Genetic Variation in IgG in Alpha 1 Antitrypsin DeficiencyUniversity of Alabama at Birmingham
- RECRUITINGNCT07152834Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway ObstructionMuğla Sıtkı Koçman University
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07193615Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)RenJi Hospital
- RECRUITINGNCT06505603PiMZ Longitudinal Cohort (PiMZ Logic)Columbia University
- RECRUITINGPHASE1NCT06996756Gene Therapy for Alpha 1- Antitrypsin DeficiencyWeill Medical College of Cornell University
- ACTIVE NOT RECRUITINGPHASE1NCT06738017Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult ParticipantsBioMarin Pharmaceutical
- ENROLLING BY INVITATIONNANCT06892236Preparation of IPSC for Cell Gene Editing for the Treatment of AATDFondazione IRCCS Policlinico San Matteo di Pavia